Slide 1: Conference call presentation FY 2021/22
Conference call presentation FY 2021/22 Update picture to match FY report Making life easier STRIVE25: SUSTAINABLE GROWTH LEADERSHIP
Slide 2: Forward-looking statements
Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements
Slide 3: Solid FY 2021/22 results in line with guidance
NEW IMAGE Solid FY 2021/22 results in line with guidance Organic Reported ROIC growth EBIT margin 6% 31% * * 27% ** *before special items **after tax and before special items 3 Cara | BM user
Slide 4: Strategic highlights from Strive25 – Sustainable growth leadership
Strategic highlights from Strive25 – Sustainable growth leadership Growth Innovation Atos Medical acquisition 31 January 2022 Chronic Care – Clinical Performance Programme • Adding a new chronic care business segment, Voice and Respiratory Care • The pivotal studies on the new catheter platform, Luj
Slide 5: FY 2021/22 organic growth of 6%, driven by a good year in Chronic Care
FY 2021/22 organic growth of 6%, driven by a good year in Chronic Care with solid growth across all regions, ex. China due to COVID-19 FY 2021/22 revenue by business area FY 2021/22 revenue by geography Business Reported revenue FY Organic growth Share of organic Geographic Reported revenue FY Organ
Slide 6: FY 2021/22 reported revenue up by 16%, impacted by the inclusion of Atos Medical
FY 2021/22 reported revenue up by 16%, impacted by the inclusion of Atos Medical and currency appreciation FY 2021/22 Revenue development (DKKm) FY 2021/22 highlights • Reported revenue increased by DKK 3,154 million or 16% vs. last year • Organic growth was 6% or DKK 1,203 million, driven by: 712 2
Slide 7: FY 2021/22 reported EBIT margin of 31%, reflecting increased commercial activity
FY 2021/22 reported EBIT margin of 31%1, reflecting an increased level of commercial activity and amortisation costs related to Atos Medical FY 2021/22 EBIT margin development before special items (%) FY 2021/22 highlights • Gross margin was 69%, on par with last year • Positive impact from: the Ato
Slide 8: FCF driven by solid underlying development in earnings
FCF driven by solid underlying development in earnings, impacted by increase in inventories and cost related to the Atos Medical acquisition FCF development1 FCF development Comments FY 2021/22 highlights • Free cash flow for FY 2021/22 was an outflow of DKK 6,660 million compared to an inflow of DK
Slide 9: FY 2022/23 guidance of 7-8% organic growth and EBIT margin of 28-30%
FY 2022/23 guidance of 7-8% organic growth and EBIT margin of 28-30% Organic revenue growth 7-8% Reported revenue growth in DKK 11-12% Reported EBIT margin 28-30% Effective tax rate Around 21% Capital expenditures Around 1.4 bn DKK 9
Slide 10: FY 2022/23 guidance breakdown: significant negative impact from input cost increases
FY 2022/23 guidance breakdown: significant negative impact from input cost increases on EBIT margin Revenue growth assumptions Key impacts on gross- and EBIT margin development in 2022/23 68.8 ILLUSTRATIVE In 2022/23, organic growth is expected at 7-8% in constant currencies 66-68% Gross margin (%)
Slide 11: We are committed to our Strive25 ambition of 7-9% organic growth
We are committed to our Strive25 ambition of 7-9% organic growth and more than 30% EBIT margin Ostomy Continence Care Voice and Care Respiratory Care Interventional Wound Urology and Skin Care more than Innovation Leadership, culture 7-9% 30% & organization organic growth EBIT margin1 p.a. Efficienc
Slide 12: Making life easier for people with intimate healthcare needs
Mission Making life easier for people with intimate healthcare needs Values Closeness… to better understand Passion… to make a difference Respect and responsibility… to guide us Vision Setting the global standard for listening and responding